Teva Pharmaceutical Industries Limited (NYSE:TEVA) went lower by -0.06% to close at $ 50.23. The company exchanged total volume of 6.39 million shares throughout course of last trade however it holds an average trading capacity of 6.12 million shares. Shares of company began trading at $50.19 climbed to high of $50.45 touched the low of $49.76.
The company is trading below its 50-day moving averages of 51.88 and down from 200-day moving averages of 56.86. The firm has price to book ratio of 1.71 and its price to sale ratio was 2.36.
Teva Pharmaceutical Industries Limited’s (TEVA) has price-to-cash ratio of 8.83 and price to sale ratio of 2.70. The company net profit margin is 8.70% and gross profit margin is 58.10%. A look on the firm performance, its monthly performance is -5.07% and a quarterly performance of -6.72%. The stock price is moving down from its 20 days moving average with -3.83% and isolated negatively from 50 days moving average with -4.40%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -2.29% and closed the trade at $ 1.71. The company recorded a trading capacity of 1.65 million shares below its three months average daily volume of 1.66 million shares. During the last trade, shares reached to high price of $1.80 and touched the low price of $1.65. The stock’s 50-day moving average is noted at $1.78 and its 200-day moving average is stands at $1.72.
Additionally, the company has EPS of -0.44. The company has market capitalization of $415.61M.
Arena Pharmaceuticals, Inc. (ARNA) reported a planned shifting of priorities to emphasize its proprietary clinical stage pipeline. The Firm also reported the implementation of additional cost reductions to streamline the organization to support its development programs.
“We believe our clinical-stage pipeline has the potential to deliver first or best-in-class compounds for a broad range of indications. Building a streamlined and highly-focused organization supports our primary objective – developing our pipeline in a timely and efficient manner,” stated Amit Munshi, Arena’s President and Chief Executive Officer.
The average true range of Arena Pharmaceuticals, Inc.’s (ARNA) is recorded at 0.11 and the relative strength index of the stock stands 43.70. The stock price is going above to its 52 week low with 31.54% and lagging behind from its 52 week high with -66.60%. Analyst recommendation for this stock stands at 2.70. A look on the firm performance, its monthly performance is -4.47% and a quarterly performance of -13.64%. The stock price is trading downbeat from its 200 days moving average with -7.82% and down from 50 days moving average with -2.61%.